Gut-Brain Axis in Schizophrenia: LBP, Zonulin, and Brain Metabolites

Introduction

Schizophrenia is a complex psychiatric disorder characterized by significant alterations in brain function and often accompanied by gastrointestinal comorbidities. Emerging research highlights the importance of the gut-brain axis in understanding its pathophysiology. This study explored the connections between markers of intestinal barrier integrity, specific brain metabolites, and reported gastrointestinal symptoms in individuals with schizophrenia and healthy controls.

The Study in Detail

The study, conducted by Turek A. et al. and published in Brain, behavior, & immunity - health (2026), aimed to assess intestinal permeability markers in conjunction with brain magnetic resonance spectroscopy (MRS) findings and gastrointestinal symptoms in schizophrenia. The researchers included 28 patients with schizophrenia (SCZ) in remission and 29 healthy control participants (CON).

Methodology involved:

• Blood tests: Measuring serum levels of lipopolysaccharide binding protein (LBP) and zonulin, both indicators of intestinal barrier permeability.
• Brain MRS 3T examination: Assessing metabolite concentrations in the anterior cingulate cortex (ACC) and posterior cingulate cortex (PCC).
• Questionnaires: Participants completed the Gastrointestinal Symptoms Rating Scale (GSRS). Schizophrenia patients were also evaluated using the Positive and Negative Syndrome Scale (PANSS).

Key findings included:

• Serum LBP levels were significantly higher in the schizophrenia group (11 ug/ml) compared to controls (7.9 ug/ml; p = 0.02). Serum zonulin levels did not differ between groups.
• Partial correlation analysis (controlling for age, ALT, HOMA-IR, and neuroleptic dose) revealed:
• A significant association between serum LBP and myo-inositol in the PCC in both SCZ (r = -0.49; p < 0.05) and CON (r = -0.46; p < 0.05) groups.
• In the SCZ group, serum zonulin correlated with glutamine in the ACC (r = -0.43; p < 0.05).
• LBP correlated with age of onset (r = -0.46; p < 0.05) and lower gastrointestinal symptoms (r = 0.54; p < 0.01) in the SCZ group.
• In healthy controls, LBP correlated with upper gastrointestinal symptoms (r = 0.53; p < 0.05).
• No significant associations were observed between PANSS subscales and LBP or zonulin levels.

Assessment

This study represents a novel exploration into the interplay between intestinal permeability, brain metabolites, and gastrointestinal symptoms in schizophrenia, being the first to combine these specific markers. The finding of elevated LBP in schizophrenia patients suggests a potential increase in systemic inflammation or altered gut barrier function in this population, even in remission. The consistent association of LBP with myo-inositol in the PCC across both groups points to a fundamental physiological role of LBP, possibly related to glial cell function, given myo-inositol's role as a glial marker.

The correlation between zonulin and glutamine in the ACC specifically in schizophrenia patients is particularly intriguing. Glutamine is a precursor for neurotransmitters like glutamate and GABA, and its dysregulation in the ACC could contribute to the complex neurochemical imbalances seen in schizophrenia. The distinct correlations of LBP with gastrointestinal symptoms in patients (lower GI) versus controls (upper GI) indicate potential differences in how gut barrier integrity issues manifest clinically in these populations.

Strengths: The study's main strength lies in its innovative approach, combining serum biomarkers with advanced brain imaging (MRS) and clinical symptom assessment. The inclusion of a control group allows for comparative analysis, and controlling for confounding factors strengthens the validity of the correlations.

Limitations: The sample size is relatively small (28 SCZ, 29 CON), which may limit the generalizability of the findings. The cross-sectional design prevents establishing causality. Furthermore, the study was conducted on patients in remission, meaning the findings might not fully capture the acute phases of schizophrenia. The use of neuroleptics in the SCZ group is a potential confounder, although the researchers attempted to control for daily neuroleptic dose in their analysis.

Practical Relevance

The findings underscore the growing understanding of the gut-brain axis's role in psychiatric disorders. For individuals with schizophrenia, the elevated LBP levels and its association with lower gastrointestinal symptoms suggest that interventions targeting gut health might be beneficial. This could include dietary modifications, probiotics, or other strategies aimed at improving intestinal barrier function and reducing systemic inflammation. While not directly actionable for individuals without schizophrenia, the observation of LBP's association with upper gastrointestinal symptoms in healthy controls further emphasizes the broad relevance of gut health markers to digestive well-being.

From a clinical perspective, these results open avenues for future research into personalized treatment approaches that consider the gut microbiome and intestinal integrity in schizophrenia. Monitoring markers like LBP could potentially serve as an additional tool for assessing disease activity or treatment response, although more research is needed to establish their clinical utility.

Conclusion

This study provides valuable insights into the intricate connections within the gut-brain axis in both healthy individuals and those with schizophrenia. It highlights elevated LBP levels and distinct correlations between intestinal permeability markers, brain metabolites, and gastrointestinal symptoms in schizophrenia patients. These findings suggest that targeting gut health may offer novel therapeutic strategies and a deeper understanding of neuroimmune dysregulation in schizophrenia.